A Possible Mechanistic Link Between the CYP2C19 Genotype, the Methadone Metabolite Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidene (EDDP), and Methadone-Induced Corrected QT Interval Prolongation in a Pilot Study

详细信息    查看全文

• 作者：John F. Carlquist ; David E. Moody ; Stacey Knight…
• 刊名：Molecular Diagnosis & Therapy
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：19
• 期：2
• 页码：131-138
• 全文大小：527 KB
• 参考文献：1.Zador D, Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990-995. Addiction. 2000;95:77-4.View Article PubMed
  2.Wagner-Servais D, Erkens M. Methadone-related deaths associated with faulty induction procedures. J Maint Addic. 2003;2:57-7.View Article
  3.Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137:501-.View Article PubMed
  4.Fanoe S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart. 2007;93:1051-.View Article PubMed Central PubMed
  5.Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res. 2005;11:44-.View Article PubMed
  6.Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med. 2006;166:1280-.View Article PubMed
  7.Straus SM, Kors JA, De Bruin ML, van der Hooft CS, Hofman A, Heeringa J, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47:362-.View Article PubMed
  8.Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC. QTc interval screening in methadone treatment. Ann Intern Med. 2009;150:387-5.View Article PubMed
  9.Eap CB, Crettol S, Rougier JS, Schlapfer J, Sintra Grilo L, Deglon JJ, et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther. 2007;81:719-8.View Article PubMed
  10.Chiang CE, Roden DM. The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol. 2000;36:1-2.View Article PubMed
  11.Ansermot N, Albayrak O, Schlapfer J, Crettol S, Croquette-Krokar M, Bourquin M, et al. Substitution of (R, S)-methadone by (R)-methadone: impact on QTc interval. Arch Intern Med. 2010;170:529-6.View Article PubMed
  12.Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41:1153-3.View Article PubMed
  13.Atkinson D, Dunne A, Parker M. Torsades de pointes and self-terminating ventricular fibrillation in a prescription methadone user. Anaesthesia. 2007;62:952-.View Article PubMed
  14.Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. Addiction. 2007;102:289-00.View Article PubMed
  15.Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf. 2005;14:747-3.View Article PubMed
  16.Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, et al. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther. 2007;82:410-6.View Article PubMed
  17.Chang Y, Fang WB, Lin SN, Moody DE. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin Pharmacol Toxicol. 2011;108:55-2.View Article PubMed Central PubMed
  18.Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther. 2007;321:389-9.View Article PubMed
  19.Crettol S, Deglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hammig R, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther. 2005;78:593-04.View Article PubMed
  20.Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006;80:668-1.View Article PubMed
  21.He P, Court MH, Greenblatt DJ, von Moltke LL. Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab Dispos. 2006;34:1198-07.View Article PubMed
  22.Fonseca F, de la Torre R, Diaz L, Pastor A, Cuyas E, Pizarro N, et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PloS One. 2011;6:e19527.View Article PubMed Central PubMed
  23.Wang SC, Ho IK, Tsou HH, Liu SW, Hsiao CF, Chen CH, et al. Functional genetic polymorphisms in CYP2C19 Gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort. OMICS. 2013;17:519-6.View Article PubMed Central PubMed
  24.Pfeufer A, Sanna
• 作者单位：John F. Carlquist (2) (5)
  David E. Moody (3)
  Stacey Knight (1)
  Eric G. Johnson (1)
  Wenfang B. Fang (3)
  John A. Huntinghouse (1)
  Jeffrey S. Rollo (1)
  Lynn R. Webster (4)
  Jeffrey L. Anderson (1) (2)
  
  2. Cardiology Division, Department of Medicine, University of Utah, Salt Lake City, UT, USA
  5. Intermountain Heart Institute, 5121 South Cottonwood Street, Murray, UT, 84107, USA
  3. Center for Human Toxicology, University of Utah, Salt Lake City, UT, USA
  1. Intermountain Heart Institute, Intermountain Healthcare, Murray, UT, USA
  4. Lifetree Clinical Research, Salt Lake City, UT, USA
  
• 刊物主题：Molecular Medicine; Human Genetics; Cancer Research; Laboratory Medicine; Pharmacotherapy;
• 出版者：Springer International Publishing
• ISSN：1179-2000

文摘

Background Methadone use and methadone-associated sudden cardiac death have increased dramatically. Prolongation of the QT interval of the cardiac cycle predisposes to arrhythmia and is common among methadone users. Objective We studied the relationship between pharmacogenetic variables and methadone metabolites and QT prolongation. Methods Blood was obtained on days 1, 7, and 21 from consenting individuals initiating methadone treatment. Plasma methadone and ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene (EDDP) were measured using liquid chromatographic–electrospray ionization–tandem mass spectrometry. The corrected QT interval (QTc) from 12-lead electrocardiograms (ECGs) was obtained at baseline and at 21?days. Results Total plasma EDDP, (S)-EDDP, and (R)-EDDP concentrations were significantly higher for individuals carrying the CYP2C19*2 variant (n?=?8) than in 17 subjects carrying the CYP2C19 wild-type allele (p?<?0.004). Seventeen (68?%) of 25 subjects experienced a QTc (Bazett) of 39.9?±?28.4?ms (mean?±?standard deviation). The methadone dose and the plasma EDDP concentration corrected for dose were both significantly associated with QTc at study termination and with change in QTc interval from baseline (?QTc) (p?<?0.03 to p?<?0.0003). Based on a QTc increase, five subjects had a potentially increased arrhythmia risk. Compared with other participants, the mean dose for those individuals was higher (50.8 vs. 42.5?mg/day; p?<?0.04) as was the total plasma EDDP (36.8 vs. 21.0?ng/mL; p?<?0.002) and dose-corrected EDDP (0.27 vs. 0.16?ng/mL/mg; p?<?0.003). Conclusions These results suggest that a notable change in the QTc interval was associated with both oral dose and increased methadone metabolism, as indicated by the higher plasma concentration of the principal methadone metabolite. The oral dose and plasma EDDP concentration may be useful in identifying individuals at risk for methadone-related arrhythmia.